Literature DB >> 2982564

Multiple sclerosis. Current concepts in management.

B Giesser.   

Abstract

Multiple sclerosis is a chronic, often progressive disease of the central nervous system which can produce visual, sensory, motor, and genitourinary dysfunction. Although there is no cure, many disabling symptoms can be ameliorated. Baclofen is the treatment of choice for spasticity and is usually given in doses of 30 to 80 mg/day, although higher doses may be used. Bladder symptoms in multiple sclerosis generally fall into the categories of failure to store, failure to empty, and mixed types. Most patients can be managed after obtaining a urine culture and sensitivity and post-voiding residual. A variety of anticholinergic agents plus intermittent self-catheterisation is usually the most effective treatment for bladder dysfunction. Prevention of infection is accomplished by urinary acidifiers or low-dose antibiotics. There is no evidence that long term use of corticosteroids has a beneficial effect on the outcome of multiple sclerosis, although they appear to be useful in hastening the recovery time from an acute exacerbation. There are a number of experimental therapeutic agents which are used to modulate the immune response, which may prove to be of use in slowing or arresting the progression of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982564     DOI: 10.2165/00003495-198529010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  24 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Experimental intrathecal administration of methylprednisolone acetate in multiple sclerosis.

Authors:  N P Goldstein; W F McGuckin; B F McKenzie; V R Mattox
Journal:  Trans Am Neurol Assoc       Date:  1970

3.  Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

Authors:  S L Hauser; D M Dawson; J R Lehrich; M F Beal; S V Kevy; R D Propper; J A Mills; H L Weiner
Journal:  N Engl J Med       Date:  1983-01-27       Impact factor: 91.245

Review 4.  Immunosuppressive drugs in multiple sclerosis: pro and con.

Authors:  G W Ellison; L W Myers
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

5.  Suppression of chronic allergic encephalomyelitis: relevance to multiple sclerosis.

Authors:  C S Raine; U Traugott; S H Stone
Journal:  Science       Date:  1978-08-04       Impact factor: 47.728

6.  Failure of basic protein therapy for multiple sclerosis.

Authors:  R E Gonsette; P Delmotte; L Demonty
Journal:  J Neurol       Date:  1977-08-18       Impact factor: 4.849

7.  Hepatitis from dantrolene sodium.

Authors:  S P Wilkinson; B Portmann; R Williams
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

8.  PPD-, PWM-, and PHA-induced interferon in stable multiple sclerosis: association with HLA-Dw2 antigen and clinical variables.

Authors:  R Salonen; J Ilonen; M Reunanen; J Nikoskelainen; A Salmi
Journal:  Ann Neurol       Date:  1982-03       Impact factor: 10.422

9.  Intrathecal interferon reduces exacerbations of multiple sclerosis.

Authors:  L Jacobs; J O'Malley; A Freeman; R Ekes
Journal:  Science       Date:  1981-11-27       Impact factor: 47.728

Review 10.  Spasticity: medical and surgical treatment.

Authors:  M R Dimitrijevic; A M Sherwood
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

View more
  2 in total

1.  Fatigue in multiple sclerosis persists over time: a longitudinal study.

Authors:  N Téllez; J Río; M Tintoré; C Nos; I Galán; X Montalban
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

2.  Simultaneous Quantitation of S(+)- and R(-)-Baclofen and Its Metabolite in Human Plasma and Cerebrospinal Fluid using LC-APCI-MS/MS: An Application for Clinical Studies.

Authors:  Qingfeng He; Yashpal S Chhonker; Matthew J McLaughlin; Daryl J Murry
Journal:  Molecules       Date:  2020-01-08       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.